{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:32:53Z","timestamp":1790465573561,"version":"4.1.0"},"reference-count":42,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The globally increasing resistance due to extended-spectrum beta-lactamase producing\n                      <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic>\n                      is a major concern. The objective of this work was to develop a murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment and to compare the fecal carriage of ESBL-producing\n                      <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      SWISS mice were treated either with ceftriaxone or with cefotaxime or with NaCl 0.9% as a control group from day 1 to day 5. We performed a gavage at day 4 with a\n                      <jats:italic toggle=\"yes\">Klebsiella pneumonia<\/jats:italic>\n                      CTX-M9. We collected stools and performed pharmacological measurements, cultures and 16S rRNA gene amplification and sequencing during the 12\u00a0days of the stool collection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mice treated with ceftriaxone were more colonized than mice treated with cefotaxime after gavage (p-value\u00a0=\u00a00.008; Kruskal-Wallis test). Ceftriaxone and cefotaxime were both excreted in large quantity in gut lumen but they drove architecture of the gut microbiota in different trajectories. Highest levels of colonization were associated with particular microbiota composition using principal coordinate analysis (PCoA) which were more often achieved in ceftriaxone-treated mice and which were preceded by highest fecal antibiotics concentrations in both cefotaxime or ceftriaxone groups. Using LEfSe, we found that twelve taxa were significantly different between cefotaxime and ceftriaxone-treated mice. Using SplinectomeR, we found that relative abundances of\n                      <jats:italic toggle=\"yes\">Klebsiella<\/jats:italic>\n                      were significantly higher in CRO than in CTX-treated mice (p-value\u00a0=\u00a00.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Ceftriaxone selects a particular microbial community and its substitution for cefotaxime could prevent the selection of extended-spectrum beta-lactamase producing\n                      <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.csbj.2021.02.019","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T11:02:10Z","timestamp":1615114930000},"page":"1423-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment"],"prefix":"10.34133","volume":"19","author":[{"given":"Matthieu","family":"Gr\u00e9goire","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Department, CHU Nantes, Nantes, France"},{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Berteau","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Bellouard","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, CHU Nantes, Nantes, France"},{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Lebastard","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Emergency Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aubert","sequence":"additional","affiliation":[{"name":"UMR Inserm 1235, The Enteric Nervous System in Gut and Brain Disorders, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Gonzales","sequence":"additional","affiliation":[{"name":"UMR Inserm 1235, The Enteric Nervous System in Gut and Brain Disorders, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Javaudin","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Emergency Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bessard","sequence":"additional","affiliation":[{"name":"UMR Inserm 1235, The Enteric Nervous System in Gut and Brain Disorders, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Bemer","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Bacteriology and Infection Control Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Batard","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Emergency Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lepelletier","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Bacteriology and Infection Control Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Neunlist","sequence":"additional","affiliation":[{"name":"UMR Inserm 1235, The Enteric Nervous System in Gut and Brain Disorders, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Montassier","sequence":"additional","affiliation":[{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"},{"name":"Emergency Department, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Dailly","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, CHU Nantes, Nantes, France"},{"name":"EE1701, Microbiotas Hosts Antibiotics and Bacterial Resistances, Nantes University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf [Internet]. [cited 2018 Aug 30]. Available from: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout J.D.D.","year":"2008","unstructured":"Pitout J.D.D. and Laupland K.B.: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008 Mar; 8: 159.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/jac\/dkq412","article-title":"Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins","volume":"66","author":"de Kraker M.E.A.","year":"2011","unstructured":"de Kraker M.E.A., Wolkewitz M., Davey P.G., Koller W., Berger J., Nagler J. et al: Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011; 66: 398.","journal-title":"J Antimicrob Chemother."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104816"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fmicb.2013.00129","article-title":"Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria","volume":"4","author":"Rupp\u00e9 E.","year":"2013","unstructured":"Rupp\u00e9 E. and Andremont A.: Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria. Front Microbiol 2013; 4: 129.","journal-title":"Front Microbiol"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1086\/422002","article-title":"The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens","volume":"39","author":"Donskey C.J.","year":"2004","unstructured":"Donskey C.J.: The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis Off Publ Infect Dis Soc Am 2004; 39: 219.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","unstructured":"Lerner A Adler A Abu-Hanna J Cohen Percia S Kazma Matalon M Carmeli Y. Spread of KPC-producing carbapenem-resistant Enterobacteriaceae: the importance of super-spreaders and rectal KPC concentration. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2015 May;21(5):470.e1-7.","DOI":"10.1016\/j.cmi.2014.12.015"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13613-017-0283-4","article-title":"Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"7","author":"Razazi K.","year":"2017","unstructured":"Razazi K., Mekontso Dessap A., Carteaux G., Jansen C., Decousser J.-W., de Prost N. et al: Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae. Ann Intensive Care 2017; 7: 61.","journal-title":"Ann Intensive Care"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10096-003-1084-2","article-title":"Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients","volume":"23","author":"Colodner R.","year":"2004","unstructured":"Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W. et al: Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2004; 23: 163.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol."},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkn534","article-title":"The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis","volume":"63","author":"Kaier K.","year":"2009","unstructured":"Kaier K., Frank U., Hagist C., Conrad A. and Meyer E.: The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother. 2009; 63: 609.","journal-title":"J Antimicrob Chemother."},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jac\/dkm225","article-title":"Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children\u2019s hospital by changing antimicrobial agent usage policy","volume":"60","author":"Lee J.","year":"2007","unstructured":"Lee J., Pai H., Kim Y.K., Kim N.H., Eun B.W., Kang H.J. et al: Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children\u2019s hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007; 60: 629.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkh282","article-title":"Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae","volume":"54","author":"Muller A.","year":"2004","unstructured":"Muller A., Lopez-Lozano J.M., Bertrand X. and Talon D.: Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004; 54: 173.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jac\/dks406","article-title":"Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes","volume":"68","author":"Gbaguidi-Haore H.","year":"2013","unstructured":"Gbaguidi-Haore H., Dumartin C., L\u2019H\u00e9riteau F., P\u00e9fau M., Hocquet D., Rogues A.-M. et al: Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother 2013; 68: 461.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkt403","article-title":"Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime","volume":"69","author":"Grohs P.","year":"2014","unstructured":"Grohs P., Kerneis S., Sabatier B., Lavollay M., Carbonnelle E., Rostane H. et al: Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 2014; 69: 786.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00134-018-5079-y","article-title":"A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in the intensive care unit","volume":"44","author":"Tan B.K.","year":"2018","unstructured":"Tan B.K., Vivier E., Bouziad K.A., Zahar J.-R., Pommier C., Parmeland L. et al: A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in the intensive care unit. Intensive Care Med 2018; 44: 672.","journal-title":"Intensive Care Med"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02244-18","article-title":"Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens","volume":"63","author":"Burdet C.","year":"2019","unstructured":"Burdet C., Grall N., Linard M., Bridier-Nahmias A., Benhayoun M., Bourabha K. et al: Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens. Antimicrob Agents Chemother 2019; 63.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1128\/AAC.00039-13","article-title":"Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by \u03b2-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice","volume":"57","author":"Grall N.","year":"2013","unstructured":"Grall N., Massias L., Nguyen T.T., Sayah-Jeanne S., Ducrot N., Chachaty E. et al: Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by \u03b2-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother 2013; 57: 5423.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.47.11.3610-3612.2003","article-title":"Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases","volume":"47","author":"Hoyen C.K.","year":"2003","unstructured":"Hoyen C.K., Pultz N.J., Paterson D.L., Aron D.C. and Donskey C.J.: Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2003; 47: 3610.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/AAC.00355-06","article-title":"Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice","volume":"51","author":"Stiefel U.","year":"2007","unstructured":"Stiefel U., Pultz N.J. and Donskey C.J.: Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 2007; 51: 372.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1128\/AAC.00194-07","article-title":"Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice","volume":"51","author":"Pultz M.J.","year":"2007","unstructured":"Pultz M.J. and Donskey C.J.: Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrob Agents Chemother 2007; 51: 3044.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1128\/AAC.03021-14","article-title":"Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model","volume":"58","author":"Hertz F.B.","year":"2014","unstructured":"Hertz F.B., L\u00f8bner-Olesen A. and Frimodt-M\u00f8ller N.: Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model. Antimicrob Agents Chemother 2014; 58: 6139.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","unstructured":"Habib G Lancellotti P Antunes MJ Bongiorni MG Casalta J-P Del Zotti F et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS) the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075\u2013128.","DOI":"10.1093\/eurheartj\/ehv319"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw861"},{"key":"e_1_3_5_25_2","first-page":"S37","article-title":"ESCMID guideline: diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek D.","year":"2016","unstructured":"van de Beek D., Cabellos C., Dzupova O., Esposito S., Klein M., Kloek A.T. et al: ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2016; 22: S37.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/infdis\/160.2.274","article-title":"Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization","volume":"160","author":"L\u00e9onard F.","year":"1989","unstructured":"L\u00e9onard F., Andremont A., Leclerq B., Labia R. and Tancr\u00e8de C.: Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J Infect Dis 1989; 160: 274.","journal-title":"J Infect Dis"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2362.1988.tb01256.x","article-title":"Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora","volume":"18","author":"Arvidsson A.","year":"1988","unstructured":"Arvidsson A., Leijd B., Nord C.E. and Angelin B.: Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. Eur J Clin Invest 1988; 18: 261.","journal-title":"Eur J Clin Invest"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.00517-15","article-title":"Limited Transmission of blaCTX-M-9-Type-Positive Escherichia coli between Humans and Poultry in Vietnam","volume":"59","author":"Ueda S.","year":"2015","unstructured":"Ueda S., Ngan B.T.K., Huong B.T.M., Hirai I., Tuyen L.D. and Yamamoto Y.: Limited Transmission of blaCTX-M-9-Type-Positive Escherichia coli between Humans and Poultry in Vietnam. Antimicrob Agents Chemother 2015; 59: 3574.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3601"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","unstructured":"Al-Ghalith GA Hillmann B Ang K Shields-Cutler R Knights D. SHI7 Is a Self-Learning Pipeline for Multipurpose Short-Read DNA Quality Control. mSystems. 2018 Jun;3(3).","DOI":"10.1128\/mSystems.00202-17"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004658","article-title":"NINJA-OPS: fast accurate marker gene alignment using concatenated ribosomes","volume":"12","author":"Al-Ghalith G.A.","year":"2016","unstructured":"Al-Ghalith G.A., Montassier E., Ward H.N. and Knights D.: NINJA-OPS: fast accurate marker gene alignment using concatenated ribosomes. PLoS Comput Biol 2016; 12: e1004658.","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03006-05"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.f.303"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2010.133"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2010.00251.x"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3389\/fmicb.2018.00785","article-title":"SplinectomeR enables group comparisons in longitudinal microbiome studies","volume":"9","author":"Shields-Cutler R.R.","year":"2018","unstructured":"Shields-Cutler R.R., Al-Ghalith G.A., Yassour M. and Knights D.: SplinectomeR enables group comparisons in longitudinal microbiome studies. Front Microbiol 2018; 9: 785.","journal-title":"Front Microbiol"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-6-r60"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2012-13-9-r79"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1093\/jac\/dky232","article-title":"Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision","volume":"73","author":"Mouton J.W.","year":"2018","unstructured":"Mouton J.W., Meletiadis J., Voss A. and Turnidge J.: Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. J Antimicrob Chemother 2018; 73: 2374.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01816732","article-title":"The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability","volume":"10","author":"Limbert M.","year":"1982","unstructured":"Limbert M., Seibert G. and Schrinner E.: The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability. Infection 1982; 10: 97.","journal-title":"Infection"},{"key":"e_1_3_5_41_2","first-page":"21S","article-title":"Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism","volume":"2","author":"Chin N.X.","year":"1984","unstructured":"Chin N.X. and Neu H.C.: Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Diagn Microbiol Infect Dis 1984; 2: 21S.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"e_1_3_5_42_2","first-page":"629","article-title":"Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli","volume":"16","author":"Marone P.","year":"1990","unstructured":"Marone P., Navarra A., Monzillo V. and Traverso A.: Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli. Drugs Exp Clin Res 1990; 16: 629.","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/14.suppl_B.45","article-title":"The action of beta-lactamases on desacetyl-cefotaxime and cefotaxime","author":"Labia R.","year":"1984","unstructured":"Labia R., Morand A. and Kazmierczak A.: The action of beta-lactamases on desacetyl-cefotaxime and cefotaxime. J Antimicrob Chemother. 1984; : 45.","journal-title":"J Antimicrob Chemother."}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2021.02.019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:44:26Z","timestamp":1779021866000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2021.02.019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"alternative-id":["10.1016\/j.csbj.2021.02.019"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2021.02.019","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2021.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}